Literature DB >> 24101401

A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals.

Thomas D Marcotte1, Reena Deutsch, Benedict Daniel Michael, Donald Franklin, Debra Rosario Cookson, Ajay R Bharti, Igor Grant, Scott L Letendre.   

Abstract

Neurocognitive (NC) impairment (NCI) occurs commonly in people living with HIV. Despite substantial effort, no biomarkers have been sufficiently validated for diagnosis and prognosis of NCI in the clinic. The goal of this project was to identify diagnostic or prognostic biomarkers for NCI in a comprehensively characterized HIV cohort. Multidisciplinary case review selected 98 HIV-infected individuals and categorized them into four NC groups using normative data: stably normal (SN), stably impaired (SI), worsening (Wo), or improving (Im). All subjects underwent comprehensive NC testing, phlebotomy, and lumbar puncture at two timepoints separated by a median of 6.2 months. Eight biomarkers were measured in CSF and blood by immunoassay. Results were analyzed using mixed model linear regression and staged recursive partitioning. At the first visit, subjects were mostly middle-aged (median 45) white (58 %) men (84 %) who had AIDS (70 %). Of the 73 % who took antiretroviral therapy (ART), 54 % had HIV RNA levels below 50 c/mL in plasma. Mixed model linear regression identified that only MCP-1 in CSF was associated with neurocognitive change group. Recursive partitioning models aimed at diagnosis (i.e., correctly classifying neurocognitive status at the first visit) were complex and required most biomarkers to achieve misclassification limits. In contrast, prognostic models were more efficient. A combination of three biomarkers (sCD14, MCP-1, SDF-1α) correctly classified 82 % of Wo and SN subjects, including 88 % of SN subjects. A combination of two biomarkers (MCP-1, TNF-α) correctly classified 81 % of Im and SI subjects, including 100 % of SI subjects. This analysis of well-characterized individuals identified concise panels of biomarkers associated with NC change. Across all analyses, the two most frequently identified biomarkers were sCD14 and MCP-1, indicators of monocyte/macrophage activation. While the panels differed depending on the outcome and on the degree of misclassification, nearly all stable patients were correctly classified.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24101401      PMCID: PMC3874146          DOI: 10.1007/s11481-013-9504-2

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  48 in total

1.  Detecting significant change in neuropsychological test performance: a comparison of four models.

Authors:  N R Temkin; R K Heaton; I Grant; S S Dikmen
Journal:  J Int Neuropsychol Soc       Date:  1999-05       Impact factor: 2.892

2.  Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection.

Authors:  Catherine L Carey; Steven Paul Woods; Raul Gonzalez; Emily Conover; Thomas D Marcotte; Igor Grant; Robert K Heaton
Journal:  J Clin Exp Neuropsychol       Date:  2004-05       Impact factor: 2.475

Review 3.  HIV-related neurocognitive impairment--a review.

Authors:  Simon Rackstraw
Journal:  Psychol Health Med       Date:  2011-07-11       Impact factor: 2.423

4.  Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection.

Authors:  Jennifer L Lyons; Hajime Uno; Petronela Ancuta; Anupa Kamat; David J Moore; Elyse J Singer; Susan Morgello; Dana Gabuzda
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-15       Impact factor: 3.731

Review 5.  Cytokine dysregulation in HIV-associated neurological disease.

Authors:  S L Wesselingh; J Glass; J C McArthur; J W Griffin; D E Griffin
Journal:  Adv Neuroimmunol       Date:  1994

6.  HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.

Authors:  R K Heaton; D B Clifford; D R Franklin; S P Woods; C Ake; F Vaida; R J Ellis; S L Letendre; T D Marcotte; J H Atkinson; M Rivera-Mindt; O R Vigil; M J Taylor; A C Collier; C M Marra; B B Gelman; J C McArthur; S Morgello; D M Simpson; J A McCutchan; I Abramson; A Gamst; C Fennema-Notestine; T L Jernigan; J Wong; I Grant
Journal:  Neurology       Date:  2010-12-07       Impact factor: 9.910

7.  Peripheral biomarkers do not correlate with cognitive impairment in highly active antiretroviral therapy-treated subjects with human immunodeficiency virus type 1 infection.

Authors:  Bing Sun; Linda Abadjian; Hans Rempel; Cyrus Calosing; Johannes Rothlind; Lynn Pulliam
Journal:  J Neurovirol       Date:  2010-03       Impact factor: 2.643

Review 8.  The macrophage: the intersection between HIV infection and atherosclerosis.

Authors:  Suzanne M Crowe; Clare L V Westhorpe; Nigora Mukhamedova; Anthony Jaworowski; Dmitri Sviridov; Michael Bukrinsky
Journal:  J Leukoc Biol       Date:  2009-12-01       Impact factor: 4.962

9.  Elevated levels of tumor necrosis factor (TNF) in the cerebrospinal fluid from patients with HIV-associated neurological disorders.

Authors:  C M Mastroianni; F Paoletti; A P Massetti; M Falciano; V Vullo
Journal:  Acta Neurol (Napoli)       Date:  1990-02

10.  HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors.

Authors:  Robert K Heaton; Donald R Franklin; Ronald J Ellis; J Allen McCutchan; Scott L Letendre; Shannon Leblanc; Stephanie H Corkran; Nichole A Duarte; David B Clifford; Steven P Woods; Ann C Collier; Christina M Marra; Susan Morgello; Monica Rivera Mindt; Michael J Taylor; Thomas D Marcotte; J Hampton Atkinson; Tanya Wolfson; Benjamin B Gelman; Justin C McArthur; David M Simpson; Ian Abramson; Anthony Gamst; Christine Fennema-Notestine; Terry L Jernigan; Joseph Wong; Igor Grant
Journal:  J Neurovirol       Date:  2010-12-21       Impact factor: 2.643

View more
  44 in total

1.  Plasma Cystatin C Associates With HIV-Associated Neurocognitive Disorder but Is a Poor Diagnostic Marker in Antiretroviral Therapy-Treated Individuals.

Authors:  Robert C Kalayjian; Kevin R Robertson; Jeffrey M Albert; Carl J Fichtenbaum; Todd T Brown; Babafemi O Taiwo
Journal:  J Acquir Immune Defic Syndr       Date:  2019-06-01       Impact factor: 3.731

2.  Activation of Cannabinoid Type Two Receptors (CB2) Diminish Inflammatory Responses in Macrophages and Brain Endothelium.

Authors:  Yuri Persidsky; Shongshan Fan; Holly Dykstra; Nancy L Reichenbach; Slava Rom; Servio H Ramirez
Journal:  J Neuroimmune Pharmacol       Date:  2015-02-11       Impact factor: 4.147

3.  Cognitive Function Among Antiretroviral Treatment-Naive Individuals Infected With Human Immunodeficiency Virus Type 1 Subtype G Versus CRF02_AG in Nigeria.

Authors:  Jibreel Jumare; Nicaise Ndembi; Samer S El-Kamary; Laurence Magder; Laura Hungerford; Tricia Burdo; Lindsay M Eyzaguirre; Patrick Dakum; Anya Umlauf; Mariana Cherner; Alash'le Abimiku; Man Charurat; William A Blattner; Walter Royal
Journal:  Clin Infect Dis       Date:  2018-04-17       Impact factor: 9.079

4.  Genome-wide association study of HIV-associated neurocognitive disorder (HAND): A CHARTER group study.

Authors:  Peilin Jia; Zhongming Zhao; Todd Hulgan; William S Bush; David C Samuels; Cinnamon S Bloss; Robert K Heaton; Ronald J Ellis; Nicholas Schork; Christina M Marra; Ann C Collier; David B Clifford; Benjamin B Gelman; Ned Sacktor; Susan Morgello; David M Simpson; J Allen McCutchan; Jill S Barnholtz-Sloan; Donald R Franklin; Debralee Rosario; Scott L Letendre; Igor Grant; Asha R Kallianpur
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-04-26       Impact factor: 3.568

5.  Investigating the role of ankyrin-rich membrane spanning protein in human immunodeficiency virus type-1 Tat-induced microglia activation.

Authors:  Vir B Singh; Alicia K Wooten; Joseph W Jackson; Sanjay B Maggirwar; Michelle Kiebala
Journal:  J Neurovirol       Date:  2015-01-31       Impact factor: 2.643

6.  Alcohol use predicts elevation in inflammatory marker soluble CD14 in men living with HIV.

Authors:  Mollie A Monnig; Christopher W Kahler; Patricia A Cioe; Lynne Tucker; Peter M Monti; Kenneth H Mayer; Bharat Ramratnam
Journal:  AIDS Care       Date:  2016-05-30

7.  Cellular Interactions and Signaling in neuroAIDS: Emerging Issues Colloquium.

Authors:  Lena Al-Harthi; Shilpa Buch; Jonathan D Geiger; Howard E Gendelman; Johnny J He; Kelly L Jordan-Sciutto; Dennis L Kolson; Jay Rappaport; Sabita Roy; Jialin Zheng; Howard S Fox
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-02       Impact factor: 4.147

8.  Changes in PINCH levels in the CSF of HIV+ individuals correlate with hpTau and CD4 count.

Authors:  Radhika Adiga; Ahmet Y Ozdemir; Alexandra Carides; Melissa Wasilewski; William Yen; Pallavi Chitturi; Ronald Ellis; Dianne Langford
Journal:  J Neurovirol       Date:  2014-05-10       Impact factor: 2.643

9.  Biomarkers for NeuroAIDS: recent progress in the field.

Authors:  Howard S Fox
Journal:  J Neuroimmune Pharmacol       Date:  2013-11-29       Impact factor: 4.147

Review 10.  HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment.

Authors:  Phillip Chan; Bruce J Brew
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.